Lily Chu

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Revision as of 00:33, May 3, 2017 by Kmdenmark (talk | contribs) (added cat)
Source: iacfsme.org

Lily Chu, MD, MSHS, is board certified in both internal medicine and geriatric medicine.[1] In 2006, she developed myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).[2]

Education[edit | edit source]

As per LinkedIn bio:[3]

  • Geriatric Medicine Fellowship, University of California, Los Angeles
  • MSHS, Public Health, University of California, Los Angeles
  • Internal Medicine Residency, University of Rochester
  • MD, University of Washington
  • BS, Biology, University of Washington

Boards and Committees[edit | edit source]

April 2013 FDA Workshop Survey[edit | edit source]

Open Letter to The Lancet[edit | edit source]

Two open letters to the editor of The Lancet urged the editor to commission a fully independent review of the PACE trial, which the journal had published in 2011. In 2016, Dr. Chu, along with 41 colleagues in the ME/CFS field, signed the second letter.

Quotes[edit | edit source]

  • 2016 - "Ultimately the best way to prevent suicide in ME/CFS will be to find effective disease-modifying treatments or cures for it."[7]

Publications[edit | edit source]

  • May 2016, Suicide and ME/CFS -- Lily Chu, MD, MSHS
  • 2012, "Exercise and chronic fatigue syndrome: maximize function, minimize post-exertional malaise," Letter to the Editor, European Journal of Clinical Investigation[8]

Notable Studies[edit | edit source]

  • 2017, Patients diagnosed with Myalgic encephalomyelitis/chronic fatigue syndrome also fit systemic exertion intolerance disease criteria

    Abstract - Background: Myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS) remains undiagnosed in up to 91% of patients. Recently, the United States-based Institute of Medicine (IOM) developed new diagnostic criteria, naming it systemic exertion intolerance disease (SEID). Purpose: We examined how subjects fit SEID criteria and existing ME/CFS case definitions early in their illness. Methods: A total of 131 subjects fitting 1994 Fukuda CFS criteria at the time of study recruitment completed a survey of symptoms they experienced during their first 6 months of illness. Symptoms were drawn from SEID and existing criteria (1994 Fukuda, 2003 Canadian Consensus Criteria (CCC), and 2011 Myalgic Encephalomyelitis-International Consensus Criteria (ME-ICC)). We calculated and compared the number/percentage of subjects fitting single or combinations of case definitions and the number/percentage of subjects with SEID experiencing orthostatic intolerance (OI) and/or cognitive impairment. Results: At 6 months of illness, SEID criteria identified 72% of all subjects, similar to when Fukuda criteria (79%) or the CCC (71%) were used, whereas the ME-ICC selected for a significantly lower percentage (61%, p < .001). When severity/frequency thresholds were added to the Fukuda criteria, CCC and ME-ICC, the percentage of these subjects also fitting SEID criteria increased to 93%, 97%, and 95%. Eighty-seven percent of SEID subjects endorsed cognitive impairment and 92%, OI; 79% experienced both symptoms. Conclusions: SEID criteria categorize a similar percentage of subjects as Fukuda criteria early in the course of ME/CFS and contain the majority of subjects identified using other criteria while requiring fewer symptoms. The advantage of SEID may be in its ease of use.[9]

Talks and Interviews[edit | edit source]

Written questions and answers to Dr. Chu's webinar

Questions to NIH during Advocacy Call[edit | edit source]

HHS/CFSAC Testimony[edit | edit source]

Online Presence[edit | edit source]

References[edit | edit source]